All companies have to make difficult choices prioritizing
objectives. In addition to other factors, pharmaceutical companies
must also consider the potential of any given clinical development
plan years before success or failure can be determined. Bringing a
product to market is costly, not only in terms of direct research
and development costs, but also the opportunity costs of potential
products that get deprioritized in a company's cost-benefit
analyses. These cost-benefit analyses have real world consequences
- it is not an understatement to say that in the pharmaceutical
field, a company's decisions, successes, and failures directly
affect the lives of its end users.
U.S. government contracts can nudge companies toward developing
drugs, countermeasures, and related diagnostics deemed essential to
U.S. public health and safety and can alter a company's
priorities. For example, programs managed by the Department of
Health and Human Services (HHS) in recent years